{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"899"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"901"}],"units":"Participants"}],"title":"Post-baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1093"}],"units":"Participants"}],"description":"Baseline evaluable participant= participant with an ADA assay result from a baseline sample(s). Post-baseline evaluable participant= participant with an ADA assay result from at least one postbaseline sample.","groups":[{"description":"Participants were administered atezolizumab 840 mg, IV infusion, Q2W in combination with chemotherapy (paclitaxel 80 mg/m\\^2, IV infusion QW for maximum of 22 weeks followed by dose-dense doxorubicin, 60 mg/m\\^2 or dose-dense epirubicin, 90 mg/m\\^2, IV (investigator's choice) plus cyclophosphamide, 600 mg/m\\^2, IV repeated Q2W for maximum of 17 weeks supported with G-CSF or GM-CSF treatment followed by atezolizumab, 1200 mg IV infusion every Q3W as a maintenance therapy to complete 1 year of atezolizumab treatment from the first dose.","id":"OG000","title":"Atezolizumab and Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Safety Evaluable Population included all participants who received any amount of any study drug. Number analyzed at baseline and postbaseline are unique number of participants out of all the assessed participants who may have been ADA positive at that timepoint. Different participants may have contributed data for baseline and postbaseline.","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Percentage of Participants With Anti-Drug Antibodies (ADAs) to Atezolizumab","type":"SECONDARY","unitOfMeasure":"percentage of participants"}